Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board.

rstCall/ - Generex Biotechnology Corporation (Nasdaq: GNBT), which is engaged in the research, development, and commercialization of drug delivery systems and technologies, announced that its Board of Directors has appointed Mark Fletcher as Interim President and Chief Executive Officer effective immediately. The Board also appointed John P. Barratt, an independent director, to serve as Chairman of the Board (see also Biotechnology).

Mr. Fletcher and Mr. Barratt succeed Anna E. Gluskin as Chief Executive Officer and President, and as Chairman, respectively. Ms. Gluskin continues as a director of the company. Mr. Fletcher has served as Generex's Executive Vice-President and …